Download PDF
Semin Thromb Hemost 2025; 51(01): 023-027
DOI: 10.1055/s-0044-1796651
Review Article

Non-factor Therapies for Hemophilia: Achievements and Perspectives

Victor Jiménez-Yuste
1   Department of Haematology, Hospital Universitario La Paz-IdiPaz, Autónoma University, Madrid, Spain
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Non-factor replacement therapies (NFTs) have been developed to address the limitations of conventional replacement therapies, aiming to improve hemostasis and provide enhanced protection against bleeding episodes and long-term joint damage for patients both with and without inhibitors. Factor VIII (FVIII)-mimetic agents, such as emicizumab, have transformed the management of hemophilia A with inhibitors, offering a lower treatment burden and an effective alternative for those without inhibitors as well. Rebalancing agents, including anti-tissular factor pathway inhibitor agents (concizumab and marstacimab) and serpin inhibitors like fitusiran, have shown promising efficacy for patients with hemophilia B with inhibitors and other hemophilia subtypes. Administered subcutaneously, NFTs generate stable thrombin levels and feature a long half-life, which can shift severe hemophilia toward a milder phenotype. These therapies are effective regardless of inhibitor status and hold potential for application in other bleeding disorders. Evaluating the potential thrombotic risk after implementing mitigation measures, along with the development of anti-drug antibodies (ADAs), remain critical areas for further analysis. NFTs pose additional challenges due to their complex mechanism of action and the absence of a standardized laboratory assessment method. Unresolved issues include optimal management strategies for major surgeries and tailored approaches for safe use in older populations. This review highlights the progress and future potential of NFTs in treating persons with hemophilia.

Keywords

hemophilia - non-factor replacement therapies - FVIII mimetics - rebalancing agents


Publication History

Article published online:
29 November 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Young G. Nonfactor therapies for hemophilia. HemaSphere 2023; 7 (06) e911
    CrossrefPubMedSearch in Google Scholar
  • 2 Mancuso ME, Croteau SE, Klamroth R. Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies. Haemophilia 2024; 30 (Suppl. 03) 39-44
    CrossrefPubMedSearch in Google Scholar
  • 3 Ljung R, Auerswald G, Benson G. et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol 2019; 102 (02) 111-122
    CrossrefPubMedSearch in Google Scholar
  • 4 Kitazawa T, Igawa T, Sampei Z. et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18 (10) 1570-1574
    CrossrefPubMedSearch in Google Scholar
  • 5 Mak S, Marszal A, Matscheko N, Rant U. Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab. MAbs 2023; 15 (01) 2149053
    CrossrefPubMedSearch in Google Scholar
  • 6 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
    CrossrefPubMedSearch in Google Scholar
  • 7 Young G, Liesner R, Chang T. et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134 (24) 2127-2138
    CrossrefPubMedSearch in Google Scholar
  • 8 Mahlangu J, Oldenburg J, Paz-Priel I. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379 (09) 811-822
    CrossrefPubMedSearch in Google Scholar
  • 9 Pipe SW, Shima M, Lehle M. et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6 (06) e295-e305
    CrossrefPubMedSearch in Google Scholar
  • 10 Pipe SW, Collins P, Dhalluin C. et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood 2024; 143 (14) 1355-1364
    CrossrefPubMedSearch in Google Scholar
  • 11 Yang R, Wang S, Wang X. et al. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemost 2022; 6 (02) e12670
    CrossrefPubMedSearch in Google Scholar
  • 12 Négrier C, Mahlangu J, Lehle M. et al. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol 2023; 10 (03) e168-e177
    CrossrefPubMedSearch in Google Scholar
  • 13 Callaghan MU, Negrier C, Paz-Priel I. et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood 2021; 137 (16) 2231-2242
    CrossrefPubMedSearch in Google Scholar
  • 14 Young G, Pipe SW, Kenet G. et al. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review. Res Pract Thromb Haemost 2024; 8 (04) 102415
    CrossrefPubMedSearch in Google Scholar
  • 15 Persson P, Amstrup AB, Coester HV, Matytsina I, Bas S. Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults. Res Pract Thromb Haemost 2023; 7 (06) 102181
    CrossrefPubMedSearch in Google Scholar
  • 16 Lauritzen B, Bjelke M, Rossen M. et al. A novel next-generation FVIII Mimetic, Mim8, has a favourable safety profile. Results from a 26-week safety study in cynomolgus monkeys. Blood 2020; 136 (Suppl. 01) 26-27
    CrossrefPubMedSearch in Google Scholar
  • 17 Mancuso ME. Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: phase 3, open-label, randomized, controlled, FRONTIER2 study. Paper presented at: ISTH Congress 2024; June 22–26, 2024 ; Bangkok
    PubMedSearch in Google Scholar
  • 18 Teranishi-Ikawa Y, Soeda T, Koga H. et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state. J Thromb Haemost 2024; 22 (02) 430-440
    CrossrefPubMedSearch in Google Scholar
  • 19 Wood JP, Ellery PER, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123 (19) 2934-2943
    CrossrefPubMedSearch in Google Scholar
  • 20 Matsushita T, Shapiro A, Abraham A. et al; explorer7 Investigators. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med 2023; 389 (09) 783-794
    CrossrefPubMedSearch in Google Scholar
  • 21 Mahlangu JN, Lamas JL, Morales JC. et al. A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol 2023; 200 (02) 229-239
    CrossrefPubMedSearch in Google Scholar
  • 22 Mahlangu J, Luis Lamas J, Cristobal Morales J. et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol 2023; 200 (02) 240-248
    CrossrefPubMedSearch in Google Scholar
  • 23 Matino D, Acharya S, Palladino A. et al. Efficacy and safety of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 BASIS Trial. Paper presented at: ASH Meeting 2023; December 9, 2023
    PubMedSearch in Google Scholar
  • 24 Kenet G, Nolan B, Zülfikar OB. et al. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX). Blood J 2024; 143: 2256-2269
    CrossrefPubMedSearch in Google Scholar
  • 25 Young G, Srivastava A, Kavakli K. et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet 2023; 401 (10386): 1427-1437
    CrossrefPubMedSearch in Google Scholar
  • 26 Srivastava A, Rangarajan S, Kavakli K. et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol 2023; 10 (05) e322-e332
    CrossrefPubMedSearch in Google Scholar
  • 27 Baglin T, Huntington JA, Koch A, Mocanu I, Makhaldiani L. Serpin-PC in persons with severe hemophilia (PwH): updated results from a multicenter multi-part, first-in-human study. Paper presented at: ASH Meeting 2023; December 10, 2023
    PubMedSearch in Google Scholar
  • 28 Leong L, Byun T, Kim B, Huck I. Pre-clinical characterization of VGA039, an anti-protein S monoclonal antibody being developed as a universal hemostatic agent for various bleeding disorders. Blood 2022; 140 (Suppl. 01) 1666-1667
    CrossrefPubMedSearch in Google Scholar
  • 29 Parnes A, Mahlangu JN, Pipe SW. et al. Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: results from the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27 (06) e772-e775
    CrossrefPubMedSearch in Google Scholar
  • 30 Skinner MW, Négrier C, Paz-Priel I. et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27 (05) 854-865
    CrossrefPubMedSearch in Google Scholar
  • 31 Kahr Rasmussen N, Berg B, Christiansen ASL. et al. The concizumab pen-injector is easy to use and preferred by hemophilia patients and caregivers: a usability study assessing pen-injector handling and preference. Patient Prefer Adherence 2024; 18: 1713-1727
    CrossrefPubMedSearch in Google Scholar
  • 32 Tran H, von Mackensen S, Abraham A. et al. Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study. Res Pract Thromb Haemost 2024; 8 (04) 102476
    CrossrefPubMedSearch in Google Scholar
  • 33 Ferrière S, Peyron I, Christophe OD. et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood 2020; 136 (06) 740-748
    CrossrefPubMedSearch in Google Scholar
  • 34 Lund J, Jensen K, Lillicrap D, Ezban M. FVIII in vitro bioequivalence of Mim8 Haemostatic effect by thrombin generation assays. Paper presented at: ISTH Congress 2024; June 22–26 2024 ; Bangkok
    PubMedSearch in Google Scholar
  • 35 Patel-Hett S, Martin EJ, Mohammed BM. et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia 2019; 25 (05) 797-806
    CrossrefPubMedSearch in Google Scholar
  • 36 Anandani G, Patel T, Parmar R. The implication of new developments in hemophilia treatment on its laboratory evaluation. Cureus 2022; 14 (10) e30212
    PubMedSearch in Google Scholar
  • 37 Sehgal A, Barros S, Ivanciu L. et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21 (05) 492-497
    CrossrefPubMedSearch in Google Scholar
  • 38 Kiialainen A, Adamkewicz JI, Petry C. et al. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks. Res Pract Thromb Haemost 2023; 8 (01) 102306
    CrossrefPubMedSearch in Google Scholar
  • 39 Pasi KJ, Lissitchkov T, Mamonov V. et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort. J Thromb Haemost 2021; 19 (06) 1436-1446
    CrossrefPubMedSearch in Google Scholar
  • 40 Dubut J, Goin V, Derray C, Huguenin Y, Fiore M. Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study. J Thromb Haemost 2024; 22 (09) 2589-2600
    CrossrefPubMedSearch in Google Scholar
  • 41 Jiménez-Yuste V, Oldenburg J, Tzeng E, Lim E, Sanabria F, Mahlangu J. Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials. Res Pract Thromb Haemost 2024; 8 (03) 102405
    CrossrefPubMedSearch in Google Scholar